Comparative Profile
| Feature | Oral Poliovirus Vaccine | Inactivated Poliovirus Vaccine |
|---|---|---|
| Preparation | Live-attenuated Sabin strains grown in monkey kidney or Vero cell cultures. | Formaldehyde-killed Salk strains grown in Vero cells, monkey kidney, or human diploid cells. |
| Administration Route | Oral administration consisting of two drops. | Intramuscular injection or intradermal fractional dose. |
| Immune Response | Induces both systemic and excellent intestinal mucosal immunity via secretory immunoglobulin A. | Induces strong systemic humoral immunity via immunoglobulin G. Weak induction of intestinal mucosal immunity. |
| Herd Effect | Confers contact immunity due to fecal shedding of vaccine virus, protecting unimmunized contacts. | Lacks contact immunity transmission. Does not significantly reduce wild virus circulation in poor sanitation settings. |
| Safety Profile | Risk of vaccine-associated paralytic poliomyelitis and circulating vaccine-derived polioviruses. | Extremely safe. Zero risk of vaccine-associated paralytic poliomyelitis or vaccine-derived polioviruses. |
| Contraindications | Contraindicated in immunodeficiency and household contacts of immunocompromised individuals. | Safe for administration in immunocompromised patients. |
| Temperature Sensitivity | Highly heat-sensitive. Potency monitored via vaccine vial monitor. | Relatively heat-stable but damaged by freezing. |
Polio Eradication And Endgame Strategic Plan
Rationale For Transition
- Wild poliovirus type 2 eradicated globally in 1999.
- Continued emergence of circulating vaccine-derived poliovirus outbreaks noted primarily in high-risk areas.
- Approximately 90 percent of all vaccine-derived poliovirus outbreaks attributed to Sabin type 2 strain.
- Vaccine-associated paralytic poliomyelitis burden necessitated shifting toward safer inactivated alternatives.
The Global Switch
- Global coordinated withdrawal of trivalent oral poliovirus vaccine executed in April 2016.
- Trivalent formulation replaced with bivalent oral poliovirus vaccine containing exclusively serotypes 1 and 3.
- Discontinuation of type 2 oral vaccine aimed at halting emergence of type 2 vaccine-derived polioviruses.
Inactivated Poliovirus Vaccine Integration
- World Health Organization mandated inclusion of at least one inactivated poliovirus vaccine dose in routine schedules globally.
- Primary objective entails inducing baseline immunity against type 2 poliovirus following bivalent vaccine transition.
- Sequential schedules utilizing inactivated vaccine prior to oral vaccine minimize vaccine-associated paralytic poliomyelitis risk while maintaining essential mucosal immunity.
- Indian national schedule incorporates fractional intradermal inactivated doses at 6 weeks, 14 weeks, and 9 to 12 months alongside oral vaccine doses.
- Ultimate endgame strategy involves complete withdrawal of all oral poliovirus vaccines and exclusive utilization of inactivated vaccines post-eradication.
Novel Developments
- Novel oral poliomyelitis vaccine type 2 developed through genetic stabilization of monovalent type 2 vaccine.
- Significantly reduced genetic reversion to neurovirulent forms compared to conventional Sabin strains.
- Deployed exclusively for targeted outbreak responses in regions experiencing circulating vaccine-derived poliovirus type 2 transmission.